AKTX PE Ratio & Valuation, Is AKTX Overvalued

Historical Valuation

Akari Therapeutics PLC (AKTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 110.51. The fair price of Akari Therapeutics PLC (AKTX) is between -- to -- according to relative valuation method.

Relative Value

Fair Zone

-----

Current Price：0.26

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Akari Therapeutics PLC (AKTX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Akari Therapeutics PLC (AKTX) has a current Price-to-Book (P/B) ratio of 0.42. Compared to its 3-year average P/B ratio of -14.70, the current P/B ratio is approximately -102.84% higher. Relative to its 5-year average P/B ratio of -1.70, the current P/B ratio is about -124.52% higher. Akari Therapeutics PLC (AKTX) has a Forward Free Cash Flow (FCF) yield of approximately -72.69%. Compared to its 3-year average FCF yield of -71.64%, the current FCF yield is approximately 1.47% lower. Relative to its 5-year average FCF yield of -55.96%, the current FCF yield is about 29.89% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for AKTX competitors is 12.98, providing a benchmark for relative valuation. Akari Therapeutics PLC Corp (AKTX.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of AKTX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of AKTX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is AKTX currently overvalued or undervalued?

What is Akari Therapeutics PLC (AKTX) fair value?

AKTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Akari Therapeutics PLC (AKTX) is between to according to relative valuation method.

How does AKTX's valuation metrics compare to the industry average?

The average P/S ratio for AKTX's competitors is 12.98, providing a benchmark for relative valuation. Akari Therapeutics PLC Corp (AKTX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Akari Therapeutics PLC (AKTX) as of Mar 12 2026?

As of Mar 12 2026, Akari Therapeutics PLC (AKTX) has a P/B ratio of 0.42. This indicates that the market values AKTX at 0.42 times its book value.

What is the current FCF Yield for Akari Therapeutics PLC (AKTX) as of Mar 12 2026?

As of Mar 12 2026, Akari Therapeutics PLC (AKTX) has a FCF Yield of -72.69%. This means that for every dollar of Akari Therapeutics PLC's market capitalization, the company generates -72.69 cents in free cash flow.

What is the current Forward P/E ratio for Akari Therapeutics PLC (AKTX) as of Mar 12 2026?

As of Mar 12 2026, Akari Therapeutics PLC (AKTX) has a Forward P/E ratio of -1.00. This means the market is willing to pay $-1.00 for every dollar of Akari Therapeutics PLC's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Akari Therapeutics PLC (AKTX) as of Mar 12 2026?

As of Mar 12 2026, Akari Therapeutics PLC (AKTX) has a Forward P/S ratio of 0.00. This means the market is valuing AKTX at $0.00 for every dollar of expected revenue over the next 12 months.

AKTX Valuation